Sphingosine-1-phosphate receptor 1 (S1PR1) modulators are an effective therapy for patients with relapsingremitting multiple sclerosis (RRMS), although considerable inter-individual variability in treatment response remains. This study aimed to investigate genetic variability within the coding regions of S1PR1 and to assess its potential association with treatment response and clinical disability measures, including the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS), in patients with RRMS. Thirty-one RRMS patients from Serbia underwent sequencing of the 5/ regulatory region and coding exons of S1PR1 using an Applied Biosystems 3130 Genetic Analyzer. Three polymorphic variants were identified. None of the analyzed variants demonstrated a significant association with treatment response. Despite the small sample size, rs41287280 showed a significant association with disability measures; in a dominant inheritance model, carriers of the G allele had lower EDSS and MSSS values (P=0.01 and P=0.006, respectively) compared with the CC genotype. In multivariable analyses, the rs41287280 G allele was associated with lower disability, whereas the rs3737577 T allele was associated with higher disability compared to the wild-type GG genotype after adjustment. These results provide preliminary evidence suggesting that S1PR1 genetic variation may be related to disease pathogenesis in RRMS, warranting further confirmation in larger, independent cohorts and, potentially, functional investigation.
Background/Objectives: Retinal optical coherence tomography (OCT) has emerged as a sensitive biomarker of neurodegeneration in multiple sclerosis (MS), yet eyes without overt optic neuritis (ON) are routinely pooled as “clinically unaffected” despite their heterogeneous histories. We evaluated whether never-ON eyes and fellow eyes after unilateral ON differ structurally and microvascularly using swept-source OCT (SS-OCT) and OCT angiography (OCTA). Methods: In this cross-sectional, single-center study, 126 clinically unaffected MS eyes—96 never-ON eyes and 30 fellow eyes after unilateral ON—were compared with 118 healthy control eyes. SS-OCT quantified ganglion cell–inner plexiform layer (GCIPL), peripapillary retinal nerve fiber layer (pRNFL), and macular RNFL (mRNFL) thickness, while OCTA measured superficial vascular plexus (SVP) vessel density. Between-group differences were assessed using generalized estimating equations with participant-level clustering, empirical (sandwich) standard errors, adjustment for age and sex, and false discovery rate correction. Results: Despite preserved visual acuity, both never-ON and fellow eyes showed structural retinal thinning relative to controls. GCIPL thickness followed a stepwise gradient—66.14 ± 4.31, 62.08 ± 7.03, and 58.03 ± 7.71 µm in controls, never-ON eyes, and fellow eyes, respectively (FDR-adjusted q = 0.020 for fellow vs. never-ON eyes)—and pRNFL and mRNFL showed a similar overall pattern. After false discovery rate correction, OCTA parameters did not differ significantly between groups. Conclusions: Clinically unaffected eyes in MS are not structurally normal, and fellow eyes after unilateral ON carry a greater burden of silent retinal damage than never-ON eyes. These two phenotypes should be analyzed separately in MS imaging research. Structural OCT measures, particularly GCIPL thickness, appear more sensitive than microvascular indices for detecting subclinical retinal involvement.